INTRODUCTION AND OBJECTIVES: Botulinum toxin is already well established as a second line therapy for the overactive detrusor, despite several drawbacks, which include an increased cost and the potential for more severe complications compared to antimuscarinics. Our study aims to investigate whether giving antimuscarinics after the toxin injection might increase the interval between intravesical treatments.
METHODS: A series of 30 consecutive adult patients were included in this prospective trial. All patients had neurogenic detrusor overactivity and were treated with intradetrusor injection of botulinum toxin type A. After one month in which the toxin proved effective, a daily dose of solifenacin 10 mg was added. The patients were evaluated every three months using the OABq (33 questions) and PVR measurement. Reinjection was decided based on the same criteria and values as the initial treatment. Urodynamics was performed before retreatment. Data was compared to a similar series of patients from our own experience. The parameters we monitored include time between injections, PVR values, OABqscore, Pdet and sensations reported by the patient. A t-test statistical analysis was done.
RESULTS: The follow up period is 24 months in this series. Six patients (20%) did not require reinjection, compared with only two patients in the reference group. The time between treatments increased by 6 AE 2.44 months (p < 0.0001). The PVR did not show any statistical significant variation, and the same was observed for the Pdet values. Detrusor overactivity was observed in all patients requiring retreatment. The OABq showed progressive degrading, with sensations worsening slower than other parameters.
CONCLUSIONS: The association between these two drug classes led to a statistically significant increase in the time between retreatments. Botulinum toxin made solifenacin effective in those cases where it didn't show enough efficacy when used alone. Antimuscarinics apparently decreased the sensation, and that might be the main reason behind longer efficacy. Even when combined with botulinum toxin, antimuscarinics did not cause acute urinary retention. The increased cost of treatment might be balanced by the longer period of efficacy.
Source of Funding: none

MP07-11 EFFICACY OF FESOTERODINE TO AMELIORATE AUTONOMIC DYSREFLEXIA IN PATIENTS WITH SPINAL CORD INJURY SUFFERING FROM NEUROGENIC DETRUSOR OVERACTIVITY
Matthias Walter*, Andrea L. Ramirez, Amanda H.X. Lee, Thomas E. Nightingale, Daniel Rapoport, Alex Kavanagh, Andrei V. Krassioukov, Vancouver, Canada INTRODUCTION AND OBJECTIVES: Neurogenic detrusor overactivity (NDO) is a leading trigger of autonomic dysreflexia (AD) in patients with spinal cord injury (SCI). Antimuscarinics, such as fesoterodine, has been shown to improve lower urinary tract (LUT) function. However, the capacity of antimuscarinics to reduce AD in patients with SCI has not been investigated yet.
METHODS: Our ethics board approved this prospective, openlabel phase II study to quantitatively assess the efficacy of fesoterodine to ameliorate AD during urodynamics (UDS) and in daily life, i.e. 24-hour ambulatory-blood-pressure-monitoring (24-h ABPM). Patients with a chronic (!1-year), traumatic SCI at or above the level of spinal segment T6, suffering from AD and NDO, underwent UDS and 24-h ABPM at baseline and before the end of the 12-week treatment period (i.e. week 11 and 12). In addition, we assessed the patients 0 quality of life (QoL) related to incontinence using the I-QoL questionnaire. Since fesoterodine could potentially affect cognitive and bowel function negatively, we monitored both using the Montreal Cognitive Assessment (MoCA) and Neurogenic Bowel Dysfunction (NBD) score.
RESULTS: Analyses of the first ten patients, who completed the study so far, revealed that fesoterodine objectively improved LUT function compared to baseline, i.e. increased maximum cystometric capacity (247AE187 vs. 472AE200mL, p[0.003) CONCLUSIONS: Our interim analyses suggest that fesoterodine has the capacity to ameliorate AD as well as to improve LUT function and incontinence-related QoL without affecting cognitive or bowel function negatively.
Source of Funding: M. Walter is a 2017 Michael Smith
Foundation for Health Research Trainee Award recipient, cofunded with the Rick Hansen Foundation. Pfizer Canada provided a Grant-in-aid including the study drug for this study.
MP07-12 THE EFFICACY OF ONABOTULINUMTOXIN A IN PATIENTS WITH PARKINSON'S DISEASE AND NEUROGENIC DETRUSOR OVERACTIVITY
INTRODUCTION AND OBJECTIVES: Patients with Parkinson's Disease (PD) and extrapyramidal syndromes often report voiding dysfunction and overactive bladder symptoms (OAB). Onabotulinum Toxin A (BTXA) injections has proven efficacy in the treatment of neurogenic OAB. We report the results of intravesical BTXA injections for treatment of drug refractory OAB in PD patients from 2 academic centers.
METHODS: We conducted a retrospective review of patients with drug refractory OAB who underwent BTXA at Concord Hospital from 2007 to 2018, and Western Health from 2013 to 2018. All patients had baseline multichannel video-urodynamic studies. Clinical outcomes and complications were obtained from medical records.
RESULTS: 31 patients (mean age 73.6) had PD. 1 patient had supranuclear palsy. 11 patients had high pressure detrusor overactivity (DO) on urodynamics, 4 had decreased compliance and the remaining 17 had low amplitude DO. 10 patients had raised post void residuals (PVR) or bladder outlet obstruction, and 5 had hypocontractile bladder The remainder had a normal voiding phase. 29 patients had an initial 100 units; 3 patients (including 2 with high pressure DO), had an initial 200 units, and 9 patients had dose escalation from an initial 100 units. 17 patients had significant improvement in storage symptoms after BTXA and 8 patients reported mild improvement. 4 of 9 patients improved with dose escalation. Overall, 26 of 32 patients had an improvement in their symptoms. The majority of patients had ongoing storage symptoms despite BTXA. 5 patients regained total continence. Post-BTXA, 11 patients had a raised PVR, 3 of whom had a normal voiding phase. 8 patients had pre-operative bladder outlet obstruction or detrusor underactivity. 5 required temporary clean intermittent self-catheterization (ISC), 1 continued pre-operative ISC and one required an SPC. This is significantly higher than the 2% retention rate post BTXA for patients with non-neurogenic OAB at our institutions
